New drug BL-M02D1 shows promise for tough cancers
NCT ID NCT05949619
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tests a new drug called BL-M02D1 in people with advanced solid tumors, including non-small cell lung cancer that has not responded to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. About 14 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.